Everything below concerns peptidase. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
| Property | Value | Notes |
|---|---|---|
| Primary route studied | Intranasal | Also examined parenterally in animal work |
| Reported plasma half-life | Minutes to tens of minutes | Values vary widely between reports |
| Main model systems | Rodent behavioural and cell assays | Human trials are few and small |
| Principal proposed targets | GABA-A receptor, GABA transaminase | Monoamine and neurotrophic pathways also reported |
| Evidence grade | Preliminary | Limited independent replication |
Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.
Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
=== Terminology === The process of translation of a documentary programme requires working with very specific, often scientific terminology. Documentary translators are not usually specialists in a given field. Therefore, they are compelled to undertake extensive research whenever asked to make a translation of a specific documentary programme in order to understand it correctly and deliver the final product free of mistakes and inaccuracies. Generally, documentaries contain a large number of specific terms, with which translators have to familiarise themselves on their own, for example:
=== Regulatory role in cell differentiation === In addition to its well-known role as a cellular energy source, glucose has been identified as a master regulator of tissue maturation. A 2025 study by Stanford Medicine uncovered that glucose, in its intact (non-metabolized) form, can bind to various regulatory proteins involved in gene expression. One such protein is IRF6, which alters its conformation upon glucose binding, thereby influencing the expression of genes associated with stem cell differentiation. This regulatory role is independent of glucose's catabolic function and has been observed across multiple tissue types, including skin, bone, fat, and white blood cells. The research demonstrated that even glucose analogs incapable of metabolism could promote differentiation, suggesting a signaling function for glucose. These findings have potential implications in understanding and treating diseases characterized by impaired differentiation, such as diabetes and certain cancers.
==== Neurological ==== Catatonia can occur due to several neurological conditions. For instance, certain types of encephalitis can cause catatonia. Anti-NMDA receptor encephalitis is a form of autoimmune encephalitis known to cause catatonia, albeit very rarely. Additionally, encephalitic catatonia has been reported in cases of severe HIV and herpes simplex virus infections. A small amount of evidence suggests that catatonia can develop after traumatic brain injury in the absence of a primary psychiatric disorder. Similarly, there are several case reports of catatonia after a stroke, with some having catatonia-associated symptoms that were unexplainable by stroke itself and which improved after treatment with benzodiazepines. Parkinson's disease can cause catatonia for some people by impairing their ability to produce and secrete dopamine, a neurotransmitter which is thought to contribute to motor dysfunction in people with catatonia.
=== Israel === Prime Minister Benjamin Netanyahu welcomed the decision to halt the strikes on Iran, but insisted that the ceasefire does not apply to the Lebanon war, contradicting Shehbaz Sharif's announcement. Netanyahu also asserted that the ceasefire was "not the end" of the military campaign against Iran, saying that "it is a stop on the way to achieving all of our objectives", which will be achieved "either by agreement, or by resuming the fighting". An advisor to Netanyahu said that Israel and the US were in "complete agreement" about current tensions. Israel's diaspora affairs minister and Likud party member Amichai Chikli called the ceasefire a "mistake", saying that "countries like these, the Japanese Empire, Nazi Germany, you need to bring them to their knees". A 13 April poll conducted by the Hebrew University of Jerusalem found that most members of the Israeli public oppose the ceasefire, with 63 percent believing that the ceasefire does not extend to Lebanon, when asked what Israel should do about Iran, 39 percent said Israel should continue attacks, 41 percent said their country should respect the ceasefire. On 29 May, a report suggested that Netanyahu and his inner political circle were privately disgruntled with Trump over his alleged subversions and cancelations of Israeli plans to topple the Iranian government and viewed the concept of an emerging American agreement with Iran as "disastrous".
Sources: en.wikipedia.org
Around half of e-cigarette company websites have a minimum age notice that prohibited underage individuals from entering. Celebrity endorsements are used to encourage e-cigarette use. Opponents of the tobacco industry state that the Blu advertisement, in a context of longstanding prohibition of tobacco advertising on television, seems to have resorted to advertising tactics that got former generations of people in the US addicted to traditional cigarettes.
Jean-Louis Sebagh is an Algerian-born French cosmetic surgeon and doctor who is known for his anti-aging surgeries, and use of botox, collagen and vitamin injections specifically on the face and neck. Sebagh's high profile clients including numerous celebrities, models and socialites include Cindy Crawford, Elle McPherson and Kylie Minogue. and he has offices in Paris and London.
Unless these long-term fiscal imbalances are addressed by reforms to these programs, raising taxes or drastic cuts in discretionary programs, the federal government will at some point be unable to pay its obligations without significant risk to the value of the dollar (inflation). By one estimate, 70% of the growth in these entitlement expenses over the 2016-2046 period is due to healthcare.
Sources: en.wikipedia.org
Directed by Bob Bee, produced by Michael Wills, made by Juniper Productions 5 September Fatal Protein, looking at the cause of CJD in humans, BSE in cattle, and scrapie in sheep; BSE was killing 1,000 British cattle a week; a brain disorders conference in Jamaica; in Papua New Guinea, the disease was called kuru or 'the laughing death', first found in the Okapa District in early 1950s by Carlton Gadjusek; Australian Michael Alpers took an interest in 1960s, at the Institute of Medical Research; epidemiologist Paul Brown of the National Institutes of Health; chimpanzees were tested on, and one suffered from ataxia; GSS, discovered in Austria, was similar, and found in Indiana; Martin Farlow, of the Indiana University Medical Center; most research was carried out on mice and hamsters; Stanley B.
== Class A peptidomimetics == This group includes modified peptides that are mainly composed of proteogenic amino acids thereby closely resembling a natural peptide binding epitope. Introduced modifications usually aim to increase the stability of the peptide, its affinity for a desired binding partner, oral availability or cell permeability. The design of class A peptidomimetics often involves macrocyclization strategies as for example in stapled peptides.
== Research == Along with the clinical trials in obesity that generated the data submitted to regulatory authorities, rimonabant was also studied in clinical trials for diabetes, atherosclerosis, and smoking cessation.
== Medical uses == In the US, sirolimus, as Rapamune, is indicated for the prevention of organ transplant rejection and for the treatment of lymphangioleiomyomatosis; and, as Fyarro, in the form of protein-bound particles, for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa). In the EU, sirolimus, as Rapamune, is indicated for the prophylaxis of organ rejection in adults at low to moderate immunological risk receiving a renal transplant and for the treatment of people with sporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function; and, as Hyftor, for the treatment of facial angiofibroma associated with tuberous sclerosis complex.
Sources: en.wikipedia.org
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.
The peptide enters plasma rapidly and is broken down by ordinary proteases into amino acids and shorter fragments. Reported half-lives are short. Whether meaningful amounts of the intact molecule reach the brain is an open question.
Most clinical reports are small, published in Russian and not independently replicated. English-language reviews highlight the absence of large randomised trials. Conclusions about efficacy should be treated as provisional.
Sealed, desiccated storage at -20 °C or colder is the standard recommendation for research-grade material. Vials should reach room temperature before they are opened, which limits condensation. Repeated temperature cycling is discouraged.